Sergi Borrego-Ecija
Overview
Explore the profile of Sergi Borrego-Ecija including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perez-Millan A, Lal-Trehan Estrada U, Falgas N, Guillen N, Borrego-Ecija S, Junca-Parella J, et al.
Eur Radiol
. 2025 Feb;
PMID: 39934339
Objectives: Frontotemporal dementia (FTD) usually shows more asymmetric atrophy patterns than Alzheimer's disease (AD). We aim to quantify this asymmetry to differentiate FTD, AD, and FTD subtypes. Methods: We studied...
2.
Sarto J, Esteller-Gauxax D, Guillen N, Falgas N, Borrego-Ecija S, Massons M, et al.
J Neurol
. 2025 Jan;
272(2):160.
PMID: 39849125
Plasma tau phosphorylated at threonine 181 (p-tau181) and 217 (p-tau217) have demonstrated high accuracy for Alzheimer's disease (AD) diagnosis, defined by CSF/PET amyloid beta (Aβ) positivity, but most studies have...
3.
Borrego-Ecija S, Junca-Parella J, Vandebergh M, Perez Millan A, Balasa M, Llado A, et al.
Neurology
. 2024 Nov;
103(11):e209944.
PMID: 39527772
Background And Objectives: Pathogenic variants in the gene cause frontotemporal dementia (FTD-) with marked brain asymmetry. This study aims to assess whether the disease progression of FTD- depends on the...
4.
Vandebergh M, Ramos E, Corriveau-Lecavalier N, Ramanan V, Kornak J, Mester C, et al.
Neurology
. 2024 Sep;
103(8):e209832.
PMID: 39321401
Background And Objectives: has been proposed as a modifier of disease risk in FTLD-TDP, particularly in pathogenic variant carriers. Furthermore, has been investigated as a disease modifier in the context...
5.
Montagut N, Borrego-Ecija S, Herrero J, Castellvi M, Balasa M, Llado A, et al.
J Speech Lang Hear Res
. 2024 Sep;
67(10):3762-3777.
PMID: 39302879
Purpose: Primary progressive aphasia (PPA) is a neurodegenerative disorder characterized by worsening of speech and/or language. Script training intervention promotes automatized speech production via repeated practice of scripted content. This...
6.
Perez-Millan A, Thirion B, Falgas N, Borrego-Ecija S, Bosch B, Junca-Parella J, et al.
Neurobiol Aging
. 2024 Sep;
144:1-11.
PMID: 39232438
Neuroimaging and fluid biomarkers are used to differentiate frontotemporal dementia (FTD) from Alzheimer's disease (AD). We implemented a machine learning algorithm that provides individual probabilistic scores based on magnetic resonance...
7.
Manzoni C, Kia D, Ferrari R, Leonenko G, Costa B, Saba V, et al.
Am J Hum Genet
. 2024 Jun;
111(7):1316-1329.
PMID: 38889728
Frontotemporal dementia (FTD) is the second most common cause of early-onset dementia after Alzheimer disease (AD). Efforts in the field mainly focus on familial forms of disease (fFTDs), while studies...
8.
Alsina R, Riba M, Perez-Millan A, Borrego-Ecija S, Aldecoa I, Romera C, et al.
Acta Neuropathol Commun
. 2024 Jun;
12(1):97.
PMID: 38879502
Wasteosomes (or corpora amylacea) are polyglucosan bodies that appear in the human brain with aging and in some neurodegenerative diseases, and have been suggested to have a potential role in...
9.
Ramos-Campoy O, Comas-Alberti A, Hervas D, Borrego-Ecija S, Bosch B, Sandoval J, et al.
Int J Mol Sci
. 2024 May;
25(10).
PMID: 38791483
Epigenetics, a potential underlying pathogenic mechanism of neurodegenerative diseases, has been in the scope of several studies performed so far. However, there is a gap in regard to analyzing different...
10.
Vandebergh M, Ramos E, Corriveau-Lecavalier N, Ramanan V, Kornak J, Mester C, et al.
medRxiv
. 2024 Apr;
PMID: 38633784
Background And Objectives: has been proposed as a modifier of disease risk in FTLD-TDP, particularly in mutation carriers. Furthermore, has been investigated as a disease modifier in the context of...